Long-term outcome in patients with myasthenia gravis: one decade longitudinal study
| Autor: | Dragana Lavrnic, Marko Kostic, Jelena Ilic Zivojinovic, Stojan Peric, Vukan Ivanovic, Ivana Basta, Ivo Bozovic |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Longitudinal study Neurology Anxiety 03 medical and health sciences Social support 0302 clinical medicine Quality of life Surveys and Questionnaires Internal medicine Myasthenia Gravis medicine Humans HARS Longitudinal Studies 030212 general & internal medicine Depression (differential diagnoses) Aged business.industry Rating scales for depression Middle Aged 3. Good health Quality of Life Female Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery |
| Zdroj: | Journal of Neurology. 269:2039-2045 |
| ISSN: | 1432-1459 0340-5354 |
| DOI: | 10.1007/s00415-021-10759-4 |
| Popis: | Even treated, myasthenia gravis (MG) continues to represent a significant burden and might continuously affect patients’ quality of life (QoL). The aim of our longitudinal study was to analyze QoL in a large cohort of MG patients after a 10-year follow-up period. This study comprised 78 MG patients (60% females, 50 ± 16 years old at baseline, 70% AchR positive) who were retested after 10 years. Disease severity was evaluated by MGFA classification. QoL was assessed using SF-36 questionnaire and Myasthenia Gravis-specific Questionnaire (MGQ). Hamilton rating scales for depression and anxiety (HDRS and HARS), Multidimensional Scale of Perceived Social Support (MSPSS) and Acceptance of Illness Scale (AIS) were also used. Similar percentage of patients was in remission at both time points (42% and 45%). However, at baseline all patients were treated, while 32% were treatment-free at follow-up. SF-36, MGQ, MSPSS and AIS scores were similar at baseline and retest. Mean HDRS and HARS scores worsened during time (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink